Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2004 Nov;12(11):491–496.

Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease

JW Jukema, M Lenselink, GJ de Grooth, SM Boekholdt, AH Liem, J-A Kuivenhoven, JJP Kastelein
PMCID: PMC2497410  PMID: 25696274

Abstract

High-density lipoprotein cholesterol (HDL-c) plays a crucial role in the concept of reverse cholesterol transport and has many other beneficial properties which may interfere with atherogenesis and plaque rupture. Low HDL-c levels are currently considered to be an important risk factor for the development of cardiovascular disease. However until recently no effective and safe treatment for powerfully increasing HDL-c selectively was available. This short overview describes possible new therapeutic approaches that may be able to raise HDL-c levels or improve HDL-c metabolism/reverse cholesterol transport. Today, the most important targets to be evaluated are inhibition of cholesteryl ester transfer protein (CETP) and increasing the HDL-c level by infusion of engineered HDL particles. Trials to prove clinical benefit of new HDL-c raising approaches are underway and may well be a new starting point for an optimised prevention and treatment of atherosclerotic cardiovascular disease.

Keywords: cardiovascular disease, cholesterol, HDL, prevention, treatment, transport

Full text

PDF
491

Images in this article

493Figure 1
on p.493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acton S., Osgood D., Donoghue M., Corella D., Pocovi M., Cenarro A., Mozas P., Keilty J., Squazzo S., Woolf E. A. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol. 1999 Jul;19(7):1734–1743. doi: 10.1161/01.atv.19.7.1734. [DOI] [PubMed] [Google Scholar]
  2. Acton S., Rigotti A., Landschulz K. T., Xu S., Hobbs H. H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996 Jan 26;271(5248):518–520. doi: 10.1126/science.271.5248.518. [DOI] [PubMed] [Google Scholar]
  3. Ashby D. T., Rye K. A., Clay M. A., Vadas M. A., Gamble J. R., Barter P. J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1450–1455. doi: 10.1161/01.atv.18.9.1450. [DOI] [PubMed] [Google Scholar]
  4. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992 Sep 15;70(7):733–737. doi: 10.1016/0002-9149(92)90550-i. [DOI] [PubMed] [Google Scholar]
  5. Attie A. D., Kastelein J. P., Hayden M. R. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001 Nov;42(11):1717–1726. [PubMed] [Google Scholar]
  6. Barter Philip J., Brewer H. Bryan, Jr, Chapman M. John, Hennekens Charles H., Rader Daniel J., Tall Alan R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):160–167. doi: 10.1161/01.atv.0000054658.91146.64. [DOI] [PubMed] [Google Scholar]
  7. Bisoendial Radjesh J., Hovingh G. Kees, Levels Johannes H. M., Lerch Peter G., Andresen Irmgard, Hayden Michael R., Kastelein John J. P., Stroes Erik S. G. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003 May 27;107(23):2944–2948. doi: 10.1161/01.CIR.0000070934.69310.1A. [DOI] [PubMed] [Google Scholar]
  8. Brown B. G., Zhao X. Q., Chait A., Fisher L. D., Cheung M. C., Morse J. S., Dowdy A. A., Marino E. K., Bolson E. L., Alaupovic P. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29;345(22):1583–1592. doi: 10.1056/NEJMoa011090. [DOI] [PubMed] [Google Scholar]
  9. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  10. Castelli W. P., Garrison R. J., Wilson P. W., Abbott R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986 Nov 28;256(20):2835–2838. [PubMed] [Google Scholar]
  11. Clee S. M., Zwinderman A. H., Engert J. C., Zwarts K. Y., Molhuizen H. O., Roomp K., Jukema J. W., van Wijland M., van Dam M., Hudson T. J. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 2001 Mar 6;103(9):1198–1205. doi: 10.1161/01.cir.103.9.1198. [DOI] [PubMed] [Google Scholar]
  12. Davidson Michael H., Maki Kevin, Umporowicz Denise, Wheeler Alistair, Rittershaus Charles, Ryan Una. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003 Jul;169(1):113–120. doi: 10.1016/s0021-9150(03)00137-0. [DOI] [PubMed] [Google Scholar]
  13. Fan L., Owen J. S., Dickson G. Construction and characterization of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase. Atherosclerosis. 1999 Nov 1;147(1):139–145. doi: 10.1016/s0021-9150(99)00191-4. [DOI] [PubMed] [Google Scholar]
  14. Franceschini G., Calabresi L., Chiesa G., Parolini C., Sirtori C. R., Canavesi M., Bernini F. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1257–1262. doi: 10.1161/01.atv.19.5.1257. [DOI] [PubMed] [Google Scholar]
  15. Franceschini G., Sirtori C. R., Capurso A., 2nd, Weisgraber K. H., Mahley R. W. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980 Nov;66(5):892–900. doi: 10.1172/JCI109956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Genest J. J., McNamara J. R., Salem D. N., Schaefer E. J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991 Jun 1;67(15):1185–1189. doi: 10.1016/0002-9149(91)90924-a. [DOI] [PubMed] [Google Scholar]
  17. Glomset J. A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968 Mar;9(2):155–167. [PubMed] [Google Scholar]
  18. Hirano K., Yamashita S., Nakajima N., Arai T., Maruyama T., Yoshida Y., Ishigami M., Sakai N., Kameda-Takemura K., Matsuzawa Y. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1053–1059. doi: 10.1161/01.atv.17.6.1053. [DOI] [PubMed] [Google Scholar]
  19. Hokanson J. E. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int J Clin Lab Res. 1997;27(1):24–34. doi: 10.1007/BF02827239. [DOI] [PubMed] [Google Scholar]
  20. Jaye M., Lynch K. J., Krawiec J., Marchadier D., Maugeais C., Doan K., South V., Amin D., Perrone M., Rader D. J. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999 Apr;21(4):424–428. doi: 10.1038/7766. [DOI] [PubMed] [Google Scholar]
  21. Jin Weijun, Marchadier Dawn, Rader Daniel J. Lipases and HDL metabolism. Trends Endocrinol Metab. 2002 May-Jun;13(4):174–178. doi: 10.1016/s1043-2760(02)00589-1. [DOI] [PubMed] [Google Scholar]
  22. King J. M., Crouse J. R., Terry J. G., Morgan T. M., Spray B. J., Miller N. E. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 1994 Oct;97(4):323–331. doi: 10.1016/0002-9343(94)90298-4. [DOI] [PubMed] [Google Scholar]
  23. Kozarsky K. F., Donahee M. H., Rigotti A., Iqbal S. N., Edelman E. R., Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature. 1997 May 22;387(6631):414–417. doi: 10.1038/387414a0. [DOI] [PubMed] [Google Scholar]
  24. Kuivenhoven J. A., Pritchard H., Hill J., Frohlich J., Assmann G., Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997 Feb;38(2):191–205. [PubMed] [Google Scholar]
  25. Ma Ke, Cilingiroglu Mehmet, Otvos James D., Ballantyne Christie M., Marian Ali J., Chan Lawrence. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A. 2003 Feb 24;100(5):2748–2753. doi: 10.1073/pnas.0438039100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Manninen V., Elo M. O., Frick M. H., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988 Aug 5;260(5):641–651. [PubMed] [Google Scholar]
  27. Martinez Laurent O., Jacquet Sébastien, Esteve Jean-Pierre, Rolland Corinne, Cabezón Elena, Champagne Eric, Pineau Thierry, Georgeaud Valérie, Walker John E., Tercé François. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003 Jan 2;421(6918):75–79. doi: 10.1038/nature01250. [DOI] [PubMed] [Google Scholar]
  28. Naqvi T. Z., Shah P. K., Ivey P. A., Molloy M. D., Thomas A. M., Panicker S., Ahmed A., Cercek B., Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol. 1999 Nov 1;84(9):1011–1017. doi: 10.1016/s0002-9149(99)00489-0. [DOI] [PubMed] [Google Scholar]
  29. Navab Mohamad, Anantharamaiah G. M., Hama Susan, Garber David W., Chaddha Manjula, Hough Greg, Lallone Roger, Fogelman Alan M. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002 Jan 22;105(3):290–292. doi: 10.1161/hc0302.103711. [DOI] [PubMed] [Google Scholar]
  30. Nissen Steven E., Tsunoda Taro, Tuzcu E. Murat, Schoenhagen Paul, Cooper Christopher J., Yasin Muhammad, Eaton Gregory M., Lauer Michael A., Sheldon W. Scott, Grines Cindy L. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003 Nov 5;290(17):2292–2300. doi: 10.1001/jama.290.17.2292. [DOI] [PubMed] [Google Scholar]
  31. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000 Jul 13;406(6792):203–207. doi: 10.1038/35018119. [DOI] [PubMed] [Google Scholar]
  32. Osgood Doreen, Corella Dolores, Demissie Serkalem, Cupples L. Adrienne, Wilson Peter W. F., Meigs James B., Schaefer Ernst J., Coltell Oscar, Ordovas Jose M. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. J Clin Endocrinol Metab. 2003 Jun;88(6):2869–2879. doi: 10.1210/jc.2002-021664. [DOI] [PubMed] [Google Scholar]
  33. Rackley C. E. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol. 1996 Sep;19(9):683–689. doi: 10.1002/clc.4960190903. [DOI] [PubMed] [Google Scholar]
  34. Rigotti A., Trigatti B. L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12610–12615. doi: 10.1073/pnas.94.23.12610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  36. Santamarina-Fojo S., Dugi K. A. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr Opin Lipidol. 1994 Apr;5(2):117–125. doi: 10.1097/00041433-199404000-00008. [DOI] [PubMed] [Google Scholar]
  37. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  38. Stalenhoef A. F., Malloy M. J., Kane J. P., Havel R. J. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci U S A. 1984 Mar;81(6):1839–1843. doi: 10.1073/pnas.81.6.1839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Séguret-Macé S., Latta-Mahieu M., Castro G., Luc G., Fruchart J. C., Rubin E., Denèfle P., Duverger N. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation. 1996 Nov 1;94(9):2177–2184. doi: 10.1161/01.cir.94.9.2177. [DOI] [PubMed] [Google Scholar]
  40. Tailleux Anne, Duriez Patrick, Fruchart Jean-Charles, Clavey Véronique. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis. 2002 Sep;164(1):1–13. doi: 10.1016/s0021-9150(01)00751-1. [DOI] [PubMed] [Google Scholar]
  41. Tall A. R. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993 Aug;34(8):1255–1274. [PubMed] [Google Scholar]
  42. Van Lenten Brian J., Wagner Alan C., Anantharamaiah G. M., Garber David W., Fishbein Michael C., Adhikary Lopa, Nayak Debi P., Hama Susan, Navab Mohamad, Fogelman Alan M. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002 Aug 27;106(9):1127–1132. doi: 10.1161/01.cir.0000030182.35880.3e. [DOI] [PubMed] [Google Scholar]
  43. Watson A. D., Berliner J. A., Hama S. Y., La Du B. N., Faull K. F., Fogelman A. M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Dec;96(6):2882–2891. doi: 10.1172/JCI118359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weisgraber K. H., Rall S. C., Jr, Bersot T. P., Mahley R. W., Franceschini G., Sirtori C. R. Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem. 1983 Feb 25;258(4):2508–2513. [PubMed] [Google Scholar]
  45. Whitlock M. E., Swenson T. L., Ramakrishnan R., Leonard M. T., Marcel Y. L., Milne R. W., Tall A. R. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest. 1989 Jul;84(1):129–137. doi: 10.1172/JCI114132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Xia P., Vadas M. A., Rye K. A., Barter P. J., Gamble J. R. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 1999 Nov 12;274(46):33143–33147. doi: 10.1074/jbc.274.46.33143. [DOI] [PubMed] [Google Scholar]
  47. Zambon Alberto, Deeb Samir S., Pauletto Paolo, Crepaldi Gaetano, Brunzell John D. Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Curr Opin Lipidol. 2003 Apr;14(2):179–189. doi: 10.1097/00041433-200304000-00010. [DOI] [PubMed] [Google Scholar]
  48. Zhong S., Sharp D. S., Grove J. S., Bruce C., Yano K., Curb J. D., Tall A. R. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996 Jun 15;97(12):2917–2923. doi: 10.1172/JCI118751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. de Grooth Greetje J., Kuivenhoven Jan Albert, Stalenhoef Anton F. H., de Graaf Jacqueline, Zwinderman Aeilko H., Posma Jan L., van Tol Arie, Kastelein John J. P. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002 May 7;105(18):2159–2165. doi: 10.1161/01.cir.0000015857.31889.7b. [DOI] [PubMed] [Google Scholar]
  50. van Tol Arie. Phospholipid transfer protein. Curr Opin Lipidol. 2002 Apr;13(2):135–139. doi: 10.1097/00041433-200204000-00004. [DOI] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES